Wednesday, 5 February 2025
  
Login

Australia's most trusted
source of pharma news

Wednesday, 5 February 2025
Ascott/IQVIA
Ascott/IQVIA
Latest News
Thriving pharma celebrates 5 years

This Founder and CEO has given an insight into what lies ahead for the business as it celebrates a successful five years of bringing medicines to fulfil unmet demand in Australia.

Vantive launches in kidney care
CEO's swansong sees a major new company created in renal therapy, bringing with it 70 years experience from its previous incarnation
TODAY
Two-thirds of big pharmas shrink
Yet a few pleased investors enough to grow the industry's total market cap
TODAY
Communicate Australia
Communicate Australia
Most Popular
Top fastest growing PBS drugs
Thirty-five drugs with the biggest growth cost the Federal Government an extra $1.4B
4 February
New drug class joins PBS
Targeted treatment for a rare type of lung cancer, the sole addition to the scheme for Feb
3 February New to the PBS
Finally... 5th time lucky at PBAC
J&J celebrates a long-awaited win but BMS left "extremely disappointed"
3 February
Top 50 PBS drugs named
The 50 medicines that accounted for more than half of the Government's overall PBS spend
31 January
Boehringer
Boehringer
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (5)

Sales & Customer Relations (20)

Clinical & Medical, R&D (9)

Regulatory, Pharmacovigilance & QA (4)

Executive Roles (1)

Other (15)

More News
Is this the future of cancer funding?
Shared private-public sector funding could turn cancer drugs into affordable, routine care for Aussies with rare cancers
TODAY
Election poll throws up a surprise
Healthcare is set to become an election battleground. Should pharma weigh in?
TODAY
Pharma political donations revealed
Which companies have given financial support to political parties?
4 February
Inside Rare Cancers roundtable
New report summarises three-part series and details what needs to be done to transform cancer care across Australia
4 February
$61M fall to generic competitors
Four brands have taken a price cut after facing generic competition for the first time
4 February
US$50B proof Novartis is on track
Shift to 'pure-play' strategy pays off with one of the strongest financial performances
4 February
Round 4: J&J Vs MSAC... again
Battle over CAR T therapy switches to drip-feed funding schedule
3 February
Telix drops $372M on US assets
Newly issued shares fund most of the buyout, with Telix picking up a top research facility in LA
3 February
Pfizer puts heat on Novo Nordisk
Competition heats up as TGA approves the second anti-TFPI antibody in Australia
3 February Approvals Action
New boss joins exclusive club
One of pharma's longest-serving CEOs to step down... see who's been tapped for the top job
31 January
Aussie sales jobs up for grabs
ICYMI: Who's hiring? Find out in the most popular stories published this week
31 January Your Week in 5 Minutes
Pharmas that love hiring Aussies
Analysis shows which companies have a higher than expected local workforce
31 January
Industry braces for 2025
Pharma is cautiously optimistic about growth but less bullish than six months ago
31 January
Shares up 125% on new drug data
After it was revealed agent significantly slowed progression of a neurological disorder with no treatment
30 January
PiF jobs
PiF jobs
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home
Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe